FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / form-of-convertible-promissory-note.docx
form-of-convertible-promissory-note.docx · 1013-00003

Parties

OFFERED FOR SA
Genome Dx Therapeutics Inc
Equity Inc
Counsel Genome Dx Therapeutics Inc
Harkness LLP
Tan LLP
Halcyon Partners LLC
Stonebridge Capital Management III LLC

Dates

September 12, 2025
March 12, 2027

Amounts

$8,000,000
$95,000,000
$0.8422
$4,000,000
$25,000,000
$840,000
$8,840,000
$16,840,000
$3,000,000
$500,000

Obligations

ANY RESALE, TRANSFER, OR OTHER DISPOSITION OF THIS NOTE OR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MUST BE MADE IN ACCORDANCE WITH THE PROVISIONS OF THE SECURITIES ACT AND THE RULES AND REGULATIONS THEREUNDER, AND THE HOLDER OF THIS NOTE, BY ACCEPTANCE HEREOF, AGREES TO BE BOUND BY THE TRANSFER RESTRICTIONS SET FORTH IN SECTION 11 OF THIS NOTE AND IN THE NOTE PURCHASE AGREEMENT REFERRED TO HEREIN
Unless otherwise defined herein, capitalized terms used in this Note shall have the meanings ascribed to them in the Purchase Agreement
For the avoidance of doubt, the Conversion Price shall be the lesser of the discount Price and the Cap Price, as calculated at the time of conversion
The actual Cap Price shall be determined as of the date of closing of the Qualified Financing based on the then-current Fully Diluted Capitalization
Interest shall accrue on the outstanding principal amount of this Note at a rate of seven percent (7
Interest shall accrue as simple interest and shall not compound at any time during the term of this Note